<?xml version="1.0"?>
<rss version="2.0">
 <channel>
  <title>StreetInsider.com News Articles</title>
  <link>http://www.streetinsider.com</link>
  <description>Latest StreetInsider.com News Articles</description>
  <language>en-us</language>
  <copyright>Copyright 2026, StreetInsider.com</copyright>
  <managingEditor>rss@streetinsider.com (SI RSS)</managingEditor>
  <webMaster>rss@streetinsider.com (SI RSS)</webMaster>
  <lastBuildDate>Wed, 03 Jun 2026 02:27:45 -0400</lastBuildDate>
  <docs>http://blogs.law.harvard.edu/tech/rss</docs>
  <image>
   <url>http://www.streetinsider.com/images/rss_logo.gif</url>
   <title>StreetInsider.com News Articles</title>
   <link>http://www.streetinsider.com</link>
   <width>143</width>
   <height>28</height>
  </image>
  <skipHours>
   <hour>0</hour>
   <hour>1</hour>
   <hour>2</hour>
   <hour>3</hour>
   <hour>21</hour>
   <hour>22</hour>
   <hour>23</hour>
  </skipHours>
  <skipDays>
   <day>Saturday</day>
   <day>Sunday</day>
  </skipDays>
  <item>
   <title>UBS Upgrades Hypera SA (HYPE3:BZ) (HYPMY) to Buy</title>
   <link>http://www.streetinsider.com/Intl+Ratings/UBS+Upgrades+Hypera+SA+%28HYPE3%3ABZ%29+%28HYPMY%29+to+Buy/26594260.html</link>
   <description>&lt;p&gt;UBS analyst Vinicius Strano upgraded Hypera SA (HYPE3:BZ) (OTC: HYPMY) from Neutral to Buy with a price target of R$28.00.&lt;/p&gt;&lt;p&gt;The analyst comments: “We upgrade HYPE from Neutral to Buy, with a price target of R$28/share. With the working capital reset complete, we believe the company is well positioned to sustain solid sell-out growth while entering a positive ROIC inflection, supporting a potential re-rating ahead. GLP-1 optionality is approaching, with a planned Semaglutide launch in 3Q26 tapping a ~R$5.2bn LTM TAM in 2026. Beyond GLP-1, HYPE is positioned to benefit from a broader set of patent cliffs and recent launches, representing</description>
   <guid isPermaLink="true">http://www.streetinsider.com/Intl+Ratings/UBS+Upgrades+Hypera+SA+%28HYPE3%3ABZ%29+%28HYPMY%29+to+Buy/26594260.html</guid>
   <pubDate>Wed, 03 Jun 2026 02:27:45 -0400</pubDate>
      	<category domain="http://rss.financialcontent.com/stocksymbol">HYPMY</category>
   	  </item>
  <item>
   <title>UBS Upgrades Hypera SA (HYPE3:BZ) (HYPMY) to Buy</title>
   <link>http://www.streetinsider.com/Upgrades/UBS+Upgrades+Hypera+SA+%28HYPE3%3ABZ%29+%28HYPMY%29+to+Buy/26594260.html</link>
   <description>&lt;p&gt;UBS analyst Vinicius Strano upgraded Hypera SA (HYPE3:BZ) (OTC: HYPMY) from Neutral to Buy with a price target of R$28.00.&lt;/p&gt;&lt;p&gt;The analyst comments: “We upgrade HYPE from Neutral to Buy, with a price target of R$28/share. With the working capital reset complete, we believe the company is well positioned to sustain solid sell-out growth while entering a positive ROIC inflection, supporting a potential re-rating ahead. GLP-1 optionality is approaching, with a planned Semaglutide launch in 3Q26 tapping a ~R$5.2bn LTM TAM in 2026. Beyond GLP-1, HYPE is positioned to benefit from a broader set of patent cliffs and recent launches, representing</description>
   <guid isPermaLink="true">http://www.streetinsider.com/Upgrades/UBS+Upgrades+Hypera+SA+%28HYPE3%3ABZ%29+%28HYPMY%29+to+Buy/26594260.html</guid>
   <pubDate>Wed, 03 Jun 2026 02:27:45 -0400</pubDate>
      	<category domain="http://rss.financialcontent.com/stocksymbol">HYPMY</category>
   	  </item>
  <item>
   <title>UBS Upgrades Hypera SA (HYPE3:BZ) (HYPMY) to Buy</title>
   <link>http://www.streetinsider.com/Analyst+Comments/UBS+Upgrades+Hypera+SA+%28HYPE3%3ABZ%29+%28HYPMY%29+to+Buy/26594260.html</link>
   <description>&lt;p&gt;UBS analyst Vinicius Strano upgraded Hypera SA (HYPE3:BZ) (OTC: HYPMY) from Neutral to Buy with a price target of R$28.00.&lt;/p&gt;&lt;p&gt;The analyst comments: “We upgrade HYPE from Neutral to Buy, with a price target of R$28/share. With the working capital reset complete, we believe the company is well positioned to sustain solid sell-out growth while entering a positive ROIC inflection, supporting a potential re-rating ahead. GLP-1 optionality is approaching, with a planned Semaglutide launch in 3Q26 tapping a ~R$5.2bn LTM TAM in 2026. Beyond GLP-1, HYPE is positioned to benefit from a broader set of patent cliffs and recent launches, representing</description>
   <guid isPermaLink="true">http://www.streetinsider.com/Analyst+Comments/UBS+Upgrades+Hypera+SA+%28HYPE3%3ABZ%29+%28HYPMY%29+to+Buy/26594260.html</guid>
   <pubDate>Wed, 03 Jun 2026 02:27:45 -0400</pubDate>
      	<category domain="http://rss.financialcontent.com/stocksymbol">HYPMY</category>
   	  </item>
  <item>
   <title>UBS Upgrades Hypera SA (HYPE3:BZ) (HYPMY) to Buy</title>
   <link>http://www.streetinsider.com/Intl+Ratings/UBS+Upgrades+Hypera+SA+%28HYPE3%3ABZ%29+%28HYPMY%29+to+Buy/26594260.html</link>
   <description>&lt;p&gt;UBS analyst Vinicius Strano upgraded Hypera SA (HYPE3:BZ) (OTC: HYPMY) from Neutral to Buy with a price target of R$28.00.&lt;/p&gt;&lt;p&gt;The analyst comments: “We upgrade HYPE from Neutral to Buy, with a price target of R$28/share. With the working capital reset complete, we believe the company is well positioned to sustain solid sell-out growth while entering a positive ROIC inflection, supporting a potential re-rating ahead. GLP-1 optionality is approaching, with a planned Semaglutide launch in 3Q26 tapping a ~R$5.2bn LTM TAM in 2026. Beyond GLP-1, HYPE is positioned to benefit from a broader set of patent cliffs and recent launches, representing</description>
   <guid isPermaLink="true">http://www.streetinsider.com/Intl+Ratings/UBS+Upgrades+Hypera+SA+%28HYPE3%3ABZ%29+%28HYPMY%29+to+Buy/26594260.html</guid>
   <pubDate>Wed, 03 Jun 2026 02:27:45 -0400</pubDate>
      	<category domain="http://rss.financialcontent.com/stocksymbol">HYPMY</category>
   	  </item>
  <item>
   <title>UBS Upgrades Hypera SA (HYPE3:BZ) (HYPMY) to Buy</title>
   <link>http://www.streetinsider.com/Upgrades/UBS+Upgrades+Hypera+SA+%28HYPE3%3ABZ%29+%28HYPMY%29+to+Buy/26594260.html</link>
   <description>&lt;p&gt;UBS analyst Vinicius Strano upgraded Hypera SA (HYPE3:BZ) (OTC: HYPMY) from Neutral to Buy with a price target of R$28.00.&lt;/p&gt;&lt;p&gt;The analyst comments: “We upgrade HYPE from Neutral to Buy, with a price target of R$28/share. With the working capital reset complete, we believe the company is well positioned to sustain solid sell-out growth while entering a positive ROIC inflection, supporting a potential re-rating ahead. GLP-1 optionality is approaching, with a planned Semaglutide launch in 3Q26 tapping a ~R$5.2bn LTM TAM in 2026. Beyond GLP-1, HYPE is positioned to benefit from a broader set of patent cliffs and recent launches, representing</description>
   <guid isPermaLink="true">http://www.streetinsider.com/Upgrades/UBS+Upgrades+Hypera+SA+%28HYPE3%3ABZ%29+%28HYPMY%29+to+Buy/26594260.html</guid>
   <pubDate>Wed, 03 Jun 2026 02:27:45 -0400</pubDate>
      	<category domain="http://rss.financialcontent.com/stocksymbol">HYPMY</category>
   	  </item>
  <item>
   <title>UBS Upgrades Hypera SA (HYPE3:BZ) (HYPMY) to Buy</title>
   <link>http://www.streetinsider.com/Analyst+Comments/UBS+Upgrades+Hypera+SA+%28HYPE3%3ABZ%29+%28HYPMY%29+to+Buy/26594260.html</link>
   <description>&lt;p&gt;UBS analyst Vinicius Strano upgraded Hypera SA (HYPE3:BZ) (OTC: HYPMY) from Neutral to Buy with a price target of R$28.00.&lt;/p&gt;&lt;p&gt;The analyst comments: “We upgrade HYPE from Neutral to Buy, with a price target of R$28/share. With the working capital reset complete, we believe the company is well positioned to sustain solid sell-out growth while entering a positive ROIC inflection, supporting a potential re-rating ahead. GLP-1 optionality is approaching, with a planned Semaglutide launch in 3Q26 tapping a ~R$5.2bn LTM TAM in 2026. Beyond GLP-1, HYPE is positioned to benefit from a broader set of patent cliffs and recent launches, representing</description>
   <guid isPermaLink="true">http://www.streetinsider.com/Analyst+Comments/UBS+Upgrades+Hypera+SA+%28HYPE3%3ABZ%29+%28HYPMY%29+to+Buy/26594260.html</guid>
   <pubDate>Wed, 03 Jun 2026 02:27:45 -0400</pubDate>
      	<category domain="http://rss.financialcontent.com/stocksymbol">HYPMY</category>
   	  </item>
  <item>
   <title>Citi Upgrades Hypera SA (HYPE3:BZ) (HYPMY) to Buy</title>
   <link>http://www.streetinsider.com/Intl+Ratings/Citi+Upgrades+Hypera+SA+%28HYPE3%3ABZ%29+%28HYPMY%29+to+Buy/26488690.html</link>
   <description>&lt;p&gt;Citi analyst Leandro Bastos upgraded Hypera SA (HYPE3:BZ) (OTC: HYPMY) from Neutral to Buy with a price target of R$28.00 (from R$26.00).&lt;/p&gt;</description>
   <guid isPermaLink="true">http://www.streetinsider.com/Intl+Ratings/Citi+Upgrades+Hypera+SA+%28HYPE3%3ABZ%29+%28HYPMY%29+to+Buy/26488690.html</guid>
   <pubDate>Thu, 14 May 2026 05:28:03 -0400</pubDate>
      	<category domain="http://rss.financialcontent.com/stocksymbol">HYPMY</category>
   	  </item>
  <item>
   <title>Citi Upgrades Hypera SA (HYPE3:BZ) (HYPMY) to Buy</title>
   <link>http://www.streetinsider.com/Upgrades/Citi+Upgrades+Hypera+SA+%28HYPE3%3ABZ%29+%28HYPMY%29+to+Buy/26488690.html</link>
   <description>&lt;p&gt;Citi analyst Leandro Bastos upgraded Hypera SA (HYPE3:BZ) (OTC: HYPMY) from Neutral to Buy with a price target of R$28.00 (from R$26.00).&lt;/p&gt;</description>
   <guid isPermaLink="true">http://www.streetinsider.com/Upgrades/Citi+Upgrades+Hypera+SA+%28HYPE3%3ABZ%29+%28HYPMY%29+to+Buy/26488690.html</guid>
   <pubDate>Thu, 14 May 2026 05:28:03 -0400</pubDate>
      	<category domain="http://rss.financialcontent.com/stocksymbol">HYPMY</category>
   	  </item>
  <item>
   <title>Citi Upgrades Hypera SA (HYPE3:BZ) (HYPMY) to Buy</title>
   <link>http://www.streetinsider.com/Analyst+PT+Change/Citi+Upgrades+Hypera+SA+%28HYPE3%3ABZ%29+%28HYPMY%29+to+Buy/26488690.html</link>
   <description>&lt;p&gt;Citi analyst Leandro Bastos upgraded Hypera SA (HYPE3:BZ) (OTC: HYPMY) from Neutral to Buy with a price target of R$28.00 (from R$26.00).&lt;/p&gt;</description>
   <guid isPermaLink="true">http://www.streetinsider.com/Analyst+PT+Change/Citi+Upgrades+Hypera+SA+%28HYPE3%3ABZ%29+%28HYPMY%29+to+Buy/26488690.html</guid>
   <pubDate>Thu, 14 May 2026 05:28:03 -0400</pubDate>
      	<category domain="http://rss.financialcontent.com/stocksymbol">HYPMY</category>
   	  </item>
  <item>
   <title>Citi Upgrades Hypera SA (HYPE3:BZ) (HYPMY) to Buy</title>
   <link>http://www.streetinsider.com/Intl+Ratings/Citi+Upgrades+Hypera+SA+%28HYPE3%3ABZ%29+%28HYPMY%29+to+Buy/26488690.html</link>
   <description>&lt;p&gt;Citi analyst Leandro Bastos upgraded Hypera SA (HYPE3:BZ) (OTC: HYPMY) from Neutral to Buy with a price target of R$28.00 (from R$26.00).&lt;/p&gt;</description>
   <guid isPermaLink="true">http://www.streetinsider.com/Intl+Ratings/Citi+Upgrades+Hypera+SA+%28HYPE3%3ABZ%29+%28HYPMY%29+to+Buy/26488690.html</guid>
   <pubDate>Thu, 14 May 2026 05:28:03 -0400</pubDate>
      	<category domain="http://rss.financialcontent.com/stocksymbol">HYPMY</category>
   	  </item>
  <item>
   <title>Citi Upgrades Hypera SA (HYPE3:BZ) (HYPMY) to Buy</title>
   <link>http://www.streetinsider.com/Upgrades/Citi+Upgrades+Hypera+SA+%28HYPE3%3ABZ%29+%28HYPMY%29+to+Buy/26488690.html</link>
   <description>&lt;p&gt;Citi analyst Leandro Bastos upgraded Hypera SA (HYPE3:BZ) (OTC: HYPMY) from Neutral to Buy with a price target of R$28.00 (from R$26.00).&lt;/p&gt;</description>
   <guid isPermaLink="true">http://www.streetinsider.com/Upgrades/Citi+Upgrades+Hypera+SA+%28HYPE3%3ABZ%29+%28HYPMY%29+to+Buy/26488690.html</guid>
   <pubDate>Thu, 14 May 2026 05:28:03 -0400</pubDate>
      	<category domain="http://rss.financialcontent.com/stocksymbol">HYPMY</category>
   	  </item>
  <item>
   <title>Citi Upgrades Hypera SA (HYPE3:BZ) (HYPMY) to Buy</title>
   <link>http://www.streetinsider.com/Analyst+PT+Change/Citi+Upgrades+Hypera+SA+%28HYPE3%3ABZ%29+%28HYPMY%29+to+Buy/26488690.html</link>
   <description>&lt;p&gt;Citi analyst Leandro Bastos upgraded Hypera SA (HYPE3:BZ) (OTC: HYPMY) from Neutral to Buy with a price target of R$28.00 (from R$26.00).&lt;/p&gt;</description>
   <guid isPermaLink="true">http://www.streetinsider.com/Analyst+PT+Change/Citi+Upgrades+Hypera+SA+%28HYPE3%3ABZ%29+%28HYPMY%29+to+Buy/26488690.html</guid>
   <pubDate>Thu, 14 May 2026 05:28:03 -0400</pubDate>
      	<category domain="http://rss.financialcontent.com/stocksymbol">HYPMY</category>
   	  </item>
  <item>
   <title>Hypera SA (HYPE3:BZ) (HYPMY) PT Raised to R$33 at JPMorgan</title>
   <link>http://www.streetinsider.com/Intl+Ratings/Hypera+SA+%28HYPE3%3ABZ%29+%28HYPMY%29+PT+Raised+to+R%2433+at+JPMorgan/25943984.html</link>
   <description>JPMorgan analyst Joseph Giordano raised the price target on Hypera SA (HYPE3:BZ) (OTC: HYPMY) to R$33.00  (from R$32.00) while maintaining a Overweight rating.</description>
   <guid isPermaLink="true">http://www.streetinsider.com/Intl+Ratings/Hypera+SA+%28HYPE3%3ABZ%29+%28HYPMY%29+PT+Raised+to+R%2433+at+JPMorgan/25943984.html</guid>
   <pubDate>Wed, 04 Feb 2026 09:00:12 -0400</pubDate>
      	<category domain="http://rss.financialcontent.com/stocksymbol">HYPMY</category>
   	  </item>
  <item>
   <title>Hypera SA (HYPE3:BZ) (HYPMY) PT Raised to R$33 at JPMorgan</title>
   <link>http://www.streetinsider.com/Analyst+PT+Change/Hypera+SA+%28HYPE3%3ABZ%29+%28HYPMY%29+PT+Raised+to+R%2433+at+JPMorgan/25943984.html</link>
   <description>JPMorgan analyst Joseph Giordano raised the price target on Hypera SA (HYPE3:BZ) (OTC: HYPMY) to R$33.00  (from R$32.00) while maintaining a Overweight rating.</description>
   <guid isPermaLink="true">http://www.streetinsider.com/Analyst+PT+Change/Hypera+SA+%28HYPE3%3ABZ%29+%28HYPMY%29+PT+Raised+to+R%2433+at+JPMorgan/25943984.html</guid>
   <pubDate>Wed, 04 Feb 2026 09:00:12 -0400</pubDate>
      	<category domain="http://rss.financialcontent.com/stocksymbol">HYPMY</category>
   	  </item>
  <item>
   <title>Hypera SA (HYPE3:BZ) (HYPMY) PT Raised to R$33 at JPMorgan</title>
   <link>http://www.streetinsider.com/Intl+Ratings/Hypera+SA+%28HYPE3%3ABZ%29+%28HYPMY%29+PT+Raised+to+R%2433+at+JPMorgan/25943984.html</link>
   <description>JPMorgan analyst Joseph Giordano raised the price target on Hypera SA (HYPE3:BZ) (OTC: HYPMY) to R$33.00  (from R$32.00) while maintaining a Overweight rating.</description>
   <guid isPermaLink="true">http://www.streetinsider.com/Intl+Ratings/Hypera+SA+%28HYPE3%3ABZ%29+%28HYPMY%29+PT+Raised+to+R%2433+at+JPMorgan/25943984.html</guid>
   <pubDate>Wed, 04 Feb 2026 09:00:12 -0400</pubDate>
      	<category domain="http://rss.financialcontent.com/stocksymbol">HYPMY</category>
   	  </item>
  <item>
   <title>Hypera SA (HYPE3:BZ) (HYPMY) PT Raised to R$33 at JPMorgan</title>
   <link>http://www.streetinsider.com/Analyst+PT+Change/Hypera+SA+%28HYPE3%3ABZ%29+%28HYPMY%29+PT+Raised+to+R%2433+at+JPMorgan/25943984.html</link>
   <description>JPMorgan analyst Joseph Giordano raised the price target on Hypera SA (HYPE3:BZ) (OTC: HYPMY) to R$33.00  (from R$32.00) while maintaining a Overweight rating.</description>
   <guid isPermaLink="true">http://www.streetinsider.com/Analyst+PT+Change/Hypera+SA+%28HYPE3%3ABZ%29+%28HYPMY%29+PT+Raised+to+R%2433+at+JPMorgan/25943984.html</guid>
   <pubDate>Wed, 04 Feb 2026 09:00:12 -0400</pubDate>
      	<category domain="http://rss.financialcontent.com/stocksymbol">HYPMY</category>
   	  </item>
  <item>
   <title>Hypera SA (HYPE3:BZ) (HYPMY) PT Lowered to R$28 at UBS</title>
   <link>http://www.streetinsider.com/Intl+Ratings/Hypera+SA+%28HYPE3%3ABZ%29+%28HYPMY%29+PT+Lowered+to+R%2428+at+UBS/25884799.html</link>
   <description>UBS lowered its price target on Hypera SA (HYPE3:BZ) (OTC: HYPMY) to R$28.00  (from R$29.00) while maintaining a Neutral rating.</description>
   <guid isPermaLink="true">http://www.streetinsider.com/Intl+Ratings/Hypera+SA+%28HYPE3%3ABZ%29+%28HYPMY%29+PT+Lowered+to+R%2428+at+UBS/25884799.html</guid>
   <pubDate>Fri, 23 Jan 2026 09:23:46 -0400</pubDate>
      	<category domain="http://rss.financialcontent.com/stocksymbol">HYPMY</category>
   	  </item>
  <item>
   <title>Hypera SA (HYPE3:BZ) (HYPMY) PT Lowered to R$28 at UBS</title>
   <link>http://www.streetinsider.com/Analyst+PT+Change/Hypera+SA+%28HYPE3%3ABZ%29+%28HYPMY%29+PT+Lowered+to+R%2428+at+UBS/25884799.html</link>
   <description>UBS lowered its price target on Hypera SA (HYPE3:BZ) (OTC: HYPMY) to R$28.00  (from R$29.00) while maintaining a Neutral rating.</description>
   <guid isPermaLink="true">http://www.streetinsider.com/Analyst+PT+Change/Hypera+SA+%28HYPE3%3ABZ%29+%28HYPMY%29+PT+Lowered+to+R%2428+at+UBS/25884799.html</guid>
   <pubDate>Fri, 23 Jan 2026 09:23:46 -0400</pubDate>
      	<category domain="http://rss.financialcontent.com/stocksymbol">HYPMY</category>
   	  </item>
  <item>
   <title>Hypera SA (HYPE3:BZ) (HYPMY) PT Lowered to R$28 at UBS</title>
   <link>http://www.streetinsider.com/Intl+Ratings/Hypera+SA+%28HYPE3%3ABZ%29+%28HYPMY%29+PT+Lowered+to+R%2428+at+UBS/25884799.html</link>
   <description>UBS lowered its price target on Hypera SA (HYPE3:BZ) (OTC: HYPMY) to R$28.00  (from R$29.00) while maintaining a Neutral rating.</description>
   <guid isPermaLink="true">http://www.streetinsider.com/Intl+Ratings/Hypera+SA+%28HYPE3%3ABZ%29+%28HYPMY%29+PT+Lowered+to+R%2428+at+UBS/25884799.html</guid>
   <pubDate>Fri, 23 Jan 2026 09:23:46 -0400</pubDate>
      	<category domain="http://rss.financialcontent.com/stocksymbol">HYPMY</category>
   	  </item>
  <item>
   <title>Hypera SA (HYPE3:BZ) (HYPMY) PT Lowered to R$28 at UBS</title>
   <link>http://www.streetinsider.com/Analyst+PT+Change/Hypera+SA+%28HYPE3%3ABZ%29+%28HYPMY%29+PT+Lowered+to+R%2428+at+UBS/25884799.html</link>
   <description>UBS lowered its price target on Hypera SA (HYPE3:BZ) (OTC: HYPMY) to R$28.00  (from R$29.00) while maintaining a Neutral rating.</description>
   <guid isPermaLink="true">http://www.streetinsider.com/Analyst+PT+Change/Hypera+SA+%28HYPE3%3ABZ%29+%28HYPMY%29+PT+Lowered+to+R%2428+at+UBS/25884799.html</guid>
   <pubDate>Fri, 23 Jan 2026 09:23:46 -0400</pubDate>
      	<category domain="http://rss.financialcontent.com/stocksymbol">HYPMY</category>
   	  </item>
  <item>
   <title>Scotiabank Starts Hypera SA (HYPE3:BZ) (HYPMY) at Sector Outperform</title>
   <link>http://www.streetinsider.com/Intl+Ratings/Scotiabank+Starts+Hypera+SA+%28HYPE3%3ABZ%29+%28HYPMY%29+at+Sector+Outperform/25061398.html</link>
   <description>&lt;p&gt;Scotiabank analyst Juan Jose Guzman initiates coverage on Hypera SA (HYPE3:BZ) (OTC: HYPMY) with a Sector Outperform rating and a price target of R$35.00.&lt;/p&gt;&lt;p&gt;The analyst comments: &quot;We have initiated coverage on the shares of Hypera S.A. (Hypera or HYPE; ticker: HYPE3-SA) with a Sector Outperform rating and a one-year target of R$35.00 per share. The company is one of the strongest consumer health and pharmaceutical operators in Brazil and the only listed equity vehicle with direct exposure to across all categories and segments of the country’s profitable, high-growth pharmaceutical industry. We like Hypera’s transformation story from a personal-care operator to</description>
   <guid isPermaLink="true">http://www.streetinsider.com/Intl+Ratings/Scotiabank+Starts+Hypera+SA+%28HYPE3%3ABZ%29+%28HYPMY%29+at+Sector+Outperform/25061398.html</guid>
   <pubDate>Thu, 17 Jul 2025 01:06:43 -0400</pubDate>
      	<category domain="http://rss.financialcontent.com/stocksymbol">HYPMY</category>
   	  </item>
  <item>
   <title>Scotiabank Starts Hypera SA (HYPE3:BZ) (HYPMY) at Sector Outperform</title>
   <link>http://www.streetinsider.com/New+Coverage/Scotiabank+Starts+Hypera+SA+%28HYPE3%3ABZ%29+%28HYPMY%29+at+Sector+Outperform/25061398.html</link>
   <description>&lt;p&gt;Scotiabank analyst Juan Jose Guzman initiates coverage on Hypera SA (HYPE3:BZ) (OTC: HYPMY) with a Sector Outperform rating and a price target of R$35.00.&lt;/p&gt;&lt;p&gt;The analyst comments: &quot;We have initiated coverage on the shares of Hypera S.A. (Hypera or HYPE; ticker: HYPE3-SA) with a Sector Outperform rating and a one-year target of R$35.00 per share. The company is one of the strongest consumer health and pharmaceutical operators in Brazil and the only listed equity vehicle with direct exposure to across all categories and segments of the country’s profitable, high-growth pharmaceutical industry. We like Hypera’s transformation story from a personal-care operator to</description>
   <guid isPermaLink="true">http://www.streetinsider.com/New+Coverage/Scotiabank+Starts+Hypera+SA+%28HYPE3%3ABZ%29+%28HYPMY%29+at+Sector+Outperform/25061398.html</guid>
   <pubDate>Thu, 17 Jul 2025 01:06:43 -0400</pubDate>
      	<category domain="http://rss.financialcontent.com/stocksymbol">HYPMY</category>
   	  </item>
  <item>
   <title>Scotiabank Starts Hypera SA (HYPE3:BZ) (HYPMY) at Sector Outperform</title>
   <link>http://www.streetinsider.com/Analyst+Comments/Scotiabank+Starts+Hypera+SA+%28HYPE3%3ABZ%29+%28HYPMY%29+at+Sector+Outperform/25061398.html</link>
   <description>&lt;p&gt;Scotiabank analyst Juan Jose Guzman initiates coverage on Hypera SA (HYPE3:BZ) (OTC: HYPMY) with a Sector Outperform rating and a price target of R$35.00.&lt;/p&gt;&lt;p&gt;The analyst comments: &quot;We have initiated coverage on the shares of Hypera S.A. (Hypera or HYPE; ticker: HYPE3-SA) with a Sector Outperform rating and a one-year target of R$35.00 per share. The company is one of the strongest consumer health and pharmaceutical operators in Brazil and the only listed equity vehicle with direct exposure to across all categories and segments of the country’s profitable, high-growth pharmaceutical industry. We like Hypera’s transformation story from a personal-care operator to</description>
   <guid isPermaLink="true">http://www.streetinsider.com/Analyst+Comments/Scotiabank+Starts+Hypera+SA+%28HYPE3%3ABZ%29+%28HYPMY%29+at+Sector+Outperform/25061398.html</guid>
   <pubDate>Thu, 17 Jul 2025 01:06:43 -0400</pubDate>
      	<category domain="http://rss.financialcontent.com/stocksymbol">HYPMY</category>
   	  </item>
  <item>
   <title>Scotiabank Starts Hypera SA (HYPE3:BZ) (HYPMY) at Sector Outperform</title>
   <link>http://www.streetinsider.com/Intl+Ratings/Scotiabank+Starts+Hypera+SA+%28HYPE3%3ABZ%29+%28HYPMY%29+at+Sector+Outperform/25061398.html</link>
   <description>&lt;p&gt;Scotiabank analyst Juan Jose Guzman initiates coverage on Hypera SA (HYPE3:BZ) (OTC: HYPMY) with a Sector Outperform rating and a price target of R$35.00.&lt;/p&gt;&lt;p&gt;The analyst comments: &quot;We have initiated coverage on the shares of Hypera S.A. (Hypera or HYPE; ticker: HYPE3-SA) with a Sector Outperform rating and a one-year target of R$35.00 per share. The company is one of the strongest consumer health and pharmaceutical operators in Brazil and the only listed equity vehicle with direct exposure to across all categories and segments of the country’s profitable, high-growth pharmaceutical industry. We like Hypera’s transformation story from a personal-care operator to</description>
   <guid isPermaLink="true">http://www.streetinsider.com/Intl+Ratings/Scotiabank+Starts+Hypera+SA+%28HYPE3%3ABZ%29+%28HYPMY%29+at+Sector+Outperform/25061398.html</guid>
   <pubDate>Thu, 17 Jul 2025 01:06:43 -0400</pubDate>
      	<category domain="http://rss.financialcontent.com/stocksymbol">HYPMY</category>
   	  </item>
  <item>
   <title>Scotiabank Starts Hypera SA (HYPE3:BZ) (HYPMY) at Sector Outperform</title>
   <link>http://www.streetinsider.com/New+Coverage/Scotiabank+Starts+Hypera+SA+%28HYPE3%3ABZ%29+%28HYPMY%29+at+Sector+Outperform/25061398.html</link>
   <description>&lt;p&gt;Scotiabank analyst Juan Jose Guzman initiates coverage on Hypera SA (HYPE3:BZ) (OTC: HYPMY) with a Sector Outperform rating and a price target of R$35.00.&lt;/p&gt;&lt;p&gt;The analyst comments: &quot;We have initiated coverage on the shares of Hypera S.A. (Hypera or HYPE; ticker: HYPE3-SA) with a Sector Outperform rating and a one-year target of R$35.00 per share. The company is one of the strongest consumer health and pharmaceutical operators in Brazil and the only listed equity vehicle with direct exposure to across all categories and segments of the country’s profitable, high-growth pharmaceutical industry. We like Hypera’s transformation story from a personal-care operator to</description>
   <guid isPermaLink="true">http://www.streetinsider.com/New+Coverage/Scotiabank+Starts+Hypera+SA+%28HYPE3%3ABZ%29+%28HYPMY%29+at+Sector+Outperform/25061398.html</guid>
   <pubDate>Thu, 17 Jul 2025 01:06:43 -0400</pubDate>
      	<category domain="http://rss.financialcontent.com/stocksymbol">HYPMY</category>
   	  </item>
 </channel>
</rss>
